Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / IPSEF - Mirati Therapeutics appoints industry veteran David Meek as new CEO

IPSEF - Mirati Therapeutics appoints industry veteran David Meek as new CEO

Ipsen Sa Ord
Mirati Therapeutics (MRTX +4.9%) has reached a four-month high amid a series of catalysts, including the appointment of the industry veteran David Meek as the new CEO. Mr. Meek will assume duties as the CEO and will join the company board effective immediately, Mirati (NASDAQ:MRTX) said in an announcement. The outgoing CEO Charles M. Baum will continue to head the R&D function of the company and remain as a board member. Mr. Meek, a former CEO of Ipsen (OTCPK:IPSEF) (OTCPK:IPSEY), has over thirty years of industry experience. He most recently served as president, CEO, and a board member of FerGene, a company focused on developing a gene therapy for bladder cancer. The announcement of leadership transition comes a day after Mirati (MRTX) demonstrated positive data for adagrasib as monotherapy and in combination with cetuximab in patients with heavily pretreated colorectal cancer having the KRASG12C mutation.

For further details see:

Mirati Therapeutics appoints industry veteran David Meek as new CEO
Stock Information
Company Name: Ipsen Sa Ord
Stock Symbol: IPSEF
Market: OTC
Menu
IPSEF IPSEF Quote IPSEF Short IPSEF News IPSEF Articles IPSEF Message Board
Get IPSEF Alerts

News, Short Squeeze, Breakout and More Instantly...